A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (NCT06752356)
A Double-blind, Randomized, Multi-Center Study Investigating Efficacy and Safety of Two Different Dosages of Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
🩺 Plain-English Summary (8th-Grade Level)
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
Who can join: Review the eligibility criteria below.
Location: USF Health - Morsani Center for Advanced Healthcare — Tampa, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- USF Health - Morsani Center for Advanced Healthcare — Tampa, Florida
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
- Advanced Neurology Epilepsy and Sleep Center/ANESC Research — El Paso, Texas
📞 Contact the Study Coordinator
Phone: +39 338 6827568
Email: a.lotti@kedrion.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Inflammatory Demyelinating Polyneuropathy
- Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP — Denton, Texas
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Homewood, Alabama
- A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP — Birmingham, Alabama
- A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) — Birmingham, Alabama
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP — Birmingham, Alabama
Explore by condition: All Chronic Inflammatory Demyelinating Polyneuropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.